Regional White Matter Atrophy−Based Classification of Multiple Sclerosis in Cross-Sectional and Longitudinal Data

References

1. 1.↵
   1. Miller DH,
   2. Barkhof F,
   3. Frank JA,
   4. et al

   ., Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125(pt 8):1676–95

   Abstract/FREE Full Text
2. 2.↵
   1. Bermel RA,
   2. Bakshi R

   . The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5:158–70

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Hauser SL,
   2. Oksenberg JR

   . The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006;52:61–76

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Owens T

   . The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003;16:259–65

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Peterson LK,
   2. Fujinami RS

   . Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007;184:37–44

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Miller DH,
   2. Leary SM

   . Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903–12

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Ge Y

   . Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 2006;27:1165–76

   Abstract/FREE Full Text
8. 8.↵
   1. Miller DH

   . Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis. NeuroRx 2004;1:284–94

   Abstract/FREE Full Text
9. 9.↵
   1. Sailer M,
   2. Fischl B,
   3. Salat BD,
   4. et al

   . Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003;126(pt 8):1734–44

   Abstract/FREE Full Text
10. 10.↵
    1. Bermel RA,
    2. Bakshi R,
    3. Tjoa RC,
    4. et al

    . Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol 2002;59:275–80

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Houtchens MK,
    2. Benedict RH,
    3. Killiany R,
    4. et al

    . Thalamic atrophy and cognition in multiple sclerosis. Neurology 2007;69:1213–23

    Abstract/FREE Full Text
12. 12.↵
    1. Liptak Z,
    2. Berger AM,
    3. Sampat MP,
    4. et al

    . Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol 2008;29:1465–70

    Abstract/FREE Full Text
13. 13.↵
    1. Pelletier J,
    2. Suchet JL,
    3. Witjas T,
    4. et al

    . A longitudinal study of callosal atrophy and interhemispheric dysfunction in relapsing-remitting multiple sclerosis. Arch Neurol 2001;58:105–11

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Gauthier SA,
    2. Glanz BI,
    3. Mandel M,
    4. et al

    . A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev 2006;5:532–36

    CrossRefPubMedWeb of Science
15. 15.↵
    1. McDonald WI,
    2. Compston A,
    3. Edan G,
    4. et al

    . Recommended diagnostic criteria for Multiple Sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–27

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Polman CH,
    2. Reingold SC,
    3. Edan G,
    4. et al

    . Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005;58:840–46

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Lublin FD,
    2. Reingold SC

    . Defining the clinical course of multiple sclerosis: results of an international survey—National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11

    Abstract/FREE Full Text
18. 18.↵
    1. Wei X,
    2. Warfield SK,
    3. Zou KH,
    4. et al

    . Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 2002;15:203–09

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Warfield SK,
    2. Kaus M,
    3. Jolesz FA,
    4. et al

    . Adaptive, template moderated, spatially varying statistical classification. Med Image Anal 2000;4:43–55

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Guttmann CR,
    2. Kikinis R,
    3. Anderson MC,
    4. et al

    . Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. J Magn Reson Imaging 1999;9:509–18

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Luft AR,
    2. Skalej M,
    3. Schulz JB,
    4. et al

    . Patterns of age-related shrinkage in cerebellum and brainstem observed in vivo using three-dimensional MRI volumetry. Cereb Cortex 1999;9:712–21

    Abstract/FREE Full Text
22. 22.↵
    1. Murshed KA,
    2. Ziylan T,
    3. Seker TM,
    4. et al

    . Morphometric assessment of brain stem und cerebellar vermis with midsagittal MRI: the gender differences and effects of age. Neuroanatomy 2003;2:35–38
23. 23.↵
    1. Rashid W,
    2. Davies GR,
    3. Chard DT,
    4. et al

    . Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 2006;77:51–55

    Abstract/FREE Full Text
24. 24.↵
    1. Vaithianathar L,
    2. Tench CR,
    3. Morgan PS,
    4. et al

    . Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis: a quantitative T1 relaxation time mapping approach. J Neurol 2003;250:307–15

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Liu C,
    2. Edwards CS,
    3. Gong Q,
    4. et al

    . Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999;66:323–30

    Abstract/FREE Full Text
26. 26.↵
    1. Rashid W,
    2. Davies GR,
    3. Chard DT,
    4. et al

    . Upper cervical cord area in early relapsing-remitting multiple sclerosis: cross-sectional study of factors influencing cord size. J Magn Reson Imaging 2006;23:473–76

    CrossRefPubMed
27. 27.↵
    1. Hofer S,
    2. Frahm J

    . Topography of the human corpus callosum revisited: comprehensive fiber tractography using diffusion tensor magnetic resonance imaging. Neuroimage 2006;32:989–94

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Duda RO,
    2. Hart PE,
    3. Stork DG

    . Pattern Classification. 2nd ed. New York: Wiley-InterScience; 2000
29. 29.↵
    1. Bieniek M,
    2. Altmann DR,
    3. Davies GR,
    4. et al

    . Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006;77:1036–39

    Abstract/FREE Full Text
30. 30.↵
    1. Losseff NA,
    2. Webb SL,
    3. O'Riordan JI,
    4. et al

    . Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119(pt 3):701–08

    Abstract/FREE Full Text
31. 31.↵
    1. Filippi M,
    2. Campi MA,
    3. Colombo B,
    4. et al

    . A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502–05

    CrossRefPubMedWeb of Science
32. 32.↵
    1. Tench CR,
    2. Morgan PS,
    3. Jaspan T,
    4. et al

    . Spinal cord imaging in multiple sclerosis. J Neuroimaging 2005;15(4 suppl):94S–102S

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Stevenson VL,
    2. Leary SM,
    3. Losseff NA,
    4. et al

    . Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234–38

    Abstract/FREE Full Text
34. 34.↵
    1. Kidd D,
    2. Thorpe JW,
    3. Thompson AJ,
    4. et al

    . Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632–37

    Abstract/FREE Full Text
35. 35.↵
    1. Simon JH,
    2. Jacobs LD,
    3. Campion MK,
    4. et al

    . A longitudinal study of brain atrophy in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1999;53:139–48

    Abstract/FREE Full Text
36. 36.↵
    1. Audoin B,
    2. Ibarrola D,
    3. Malikova I,
    4. et al

    . Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis: a two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler 2007;13:41–51

    Abstract/FREE Full Text
37. 37.↵
    1. Martola J,
    2. Stawiarz JL,
    3. Fredrikson S,
    4. et al

    . Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. J Neurol Neurosurg Psychiatry 2007;78:375–80

    Abstract/FREE Full Text
38. 38.↵
    1. Evangelou N,
    2. Esiri MM,
    3. Smith S,
    4. et al

    . Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391–95

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Witelson SF

    . Hand and sex differences in the isthmus and genu of the human corpus callosum: a postmortem morphological study. Brain 1989;112(pt 3):799–835

    Abstract/FREE Full Text
40. 40.↵
    1. Jokinen H,
    2. Ryberg C,
    3. Kalska H,
    4. et al

    . Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. J Neurol Neurosurg Psychiatry 2007;78:491–96

    Abstract/FREE Full Text
41. 41.↵
    1. Huijbregts SC,
    2. Kalkers NF,
    3. de Sonneville LM,
    4. et al

    . Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004;63:335–39

    Abstract/FREE Full Text
42. 42.↵
    1. Foong J,
    2. Rozewicz L,
    3. Chong WK,
    4. et al

    . A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis. J Neurol 2000;247:97–101

    CrossRefPubMedWeb of Science
43. 43.↵
    1. Comi G,
    2. Filippi M,
    3. Martinelli V,
    4. et al

    . Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. J Neurol Sci 1995;132:222–27

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Oh J,
    2. Pelletier D,
    3. Nelson SJ

    . Corpus callosum axonal injury in multiple sclerosis measured by proton magnetic resonance spectroscopic imaging. Arch Neurol 2004;61:1081–86

    CrossRefPubMedWeb of Science
45. 45.↵
    1. DeLuca GC,
    2. Ebers GC,
    3. Esiri MM

    . Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127(pt 5):1009–18

    Abstract/FREE Full Text
46. 46.↵
    1. Gilmore CP,
    2. DeLuca GC,
    3. Bo L,
    4. et al

    . Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch Neurol 2005;62:1859–62

    CrossRefPubMedWeb of Science
47. 47.↵
    1. Ann Marrie R,
    2. Rudick RA

    . Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006;2:34–44

    CrossRefPubMedWeb of Science
48. 48.↵
    1. Evangelou N,
    2. Konz D,
    3. Esiri MM,
    4. et al

    . Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. Brain 2001;124(pt 9):1813–20

    Abstract/FREE Full Text
49. 49.↵
    1. Ciccarelli O,
    2. Werring DJ,
    3. Barker GJ,
    4. et al

    . A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging–evidence of wallerian degeneration. J Neurol 2003;250:287–92

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Coombs BD,
    2. Best A,
    3. Brown MS,
    4. et al

    . Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Mult Scler 2004;10:392–97

    Abstract/FREE Full Text
51. 51.↵
    1. Ge Y,
    2. Law M,
    3. Johnson G,
    4. et al

    . Preferential occult injury of corpus callosum in multiple sclerosis measured by diffusion tensor imaging. JMRI 2004;20:1–7

    CrossRefPubMed
52. 52.↵
    1. Lin X,
    2. Tench CR,
    3. Morgan PS,
    4. et al

    . Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatr 2008;79:437–41

    Abstract/FREE Full Text
53. 53.↵
    1. Mesaros S,
    2. Rocca MA,
    3. Riccitelli G,
    4. et al

    . Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 2009;30:2656–66

    CrossRefPubMedWeb of Science
54. 54.↵
    1. Raininko R,
    2. Autti T,
    3. Vanhanen SL,
    4. et al

    . The normal brain stem from infancy to old age. A morphometric MRI study. Neuroradiology 1994;36:364–68

    CrossRefPubMedWeb of Science
55. 55.↵
    1. Mitchell TN,
    2. Free SL,
    3. Merschhemke M,
    4. et al

    . Reliable callosal measurement: population normative data confirm sex-related differences. AJNR Am J Neuroradiol 2003;24:410–18

    Abstract/FREE Full Text
56. 56.↵
    1. Sullivan EV,
    2. Rosenbloom MJ,
    3. Desmond JE,
    4. et al

    . Sex differences in corpus callosum size: relationship to age and intracranial size. Neurobiol Aging 2001;22:603–11

    CrossRefPubMedWeb of Science